Abstract

Recombinant monoclonal antibodies (rmAbs) will become part of the therapeutical arsenal for numerous pathologies, The generalization of their usage will be driven by faster development program and lower production costs, both criteria being directly dependent on the productivity of our bioprocesses. During the past decades impressive progresses have been made regarding the bioproduction equipment’s, cell models and purification processes. The improvement of the biomolecular components, that are the plasmids, has somewhat lagged behind such developments. With the booming of molecular technologies of DNA assembly methods, including the proprietary e-Zyvec® method from Polyplus®, we have new opportunities to explore the potential of plasmid engineering as another leverage to increase yield and quality of rmAbs bioproduction.

Download Poster on improving mAbs yield and quality through plasmid engineering

Fill out the below form with the requested details to download the poster